Compare Infosys Limited (INFY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Inovio Pharmaceuticals Inc — how do they compare? Infosys Limited trades at $11.23 (market cap $46.65B), while Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M). The key difference: Infosys Limited is far larger — about 522.6× Inovio Pharmaceuticals Inc's market cap, and Infosys Limited pays a 4.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INFY | INO | |
|---|---|---|
Market Cap | $46.65B | $89.27M |
Sector | Technology | Health |
52-Week High | $20.22 | $2.87 |
52-Week Low | $10.49 | $1.05 |
Enterprise Value | $43.87B | $60.28M |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.31, down 1.57% on the day, with a bullish technical signal despite bearish moving averages. The stock shows strong profitability with a 16.44% net income margin and 31.57% ROE, supported by recent earnings beats. Recent news highlights AI collaborations with firms like Sentara and GlobalFoundries, positioning the company for growth in enterprise AI services.
The outlook is cautiously optimistic with a consensus price target of $12.28, implying 8.6% upside. Risks include competitive pressures in IT services and potential volatility from sector-wide demand concerns, as seen with Accenture's recent outlook. Analyst sentiment is mixed, with 37.5% buy ratings but a majority hold stance, reflecting balanced near-term expectations.
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
